Bio-Rad Laboratories - BIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $680.00
  • Forecasted Upside: 70.68 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$398.41
▼ -5.65 (-1.40%)

This chart shows the closing price for BIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bio-Rad Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIO

Analyst Price Target is $680.00
▲ +70.68% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is $680.00, with a high forecast of $700.00 and a low forecast of $640.00. The average price target represents a 70.68% upside from the last price of $398.41.

This chart shows the closing price for BIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Bio-Rad Laboratories. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/28/2022Credit Suisse GroupLower TargetOutperform$715.00 ➝ $640.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$715.00Low
7/8/2022CitigroupLower TargetBuy$750.00 ➝ $700.00N/A
5/2/2022CitigroupLower Target$800.00 ➝ $750.00Medium
4/29/2022Jefferies Financial GroupReiterated RatingBuy$700.00High
2/11/2022CitigroupBoost Target$750.00 ➝ $800.00Low
1/28/2022CitigroupLower TargetBuy$915.00 ➝ $750.00High
7/30/2021Wells Fargo & CompanyBoost TargetOverweight$735.00 ➝ $930.00High
2/12/2021CitigroupBoost TargetBuy$675.00 ➝ $750.00Low
2/5/2021Jefferies Financial GroupBoost TargetBuy$660.00 ➝ $725.00Low
10/30/2020Smith Barney CitigroupBoost Target$625.00 ➝ $675.00Medium
10/30/2020Wells Fargo & CompanyBoost TargetOverweight$590.00 ➝ $650.00High
9/3/2020Jefferies Financial GroupReiterated RatingBuy ➝ Market Perform$666.00Medium
9/3/2020Wells Fargo & CompanyReiterated RatingBuy$590.00Medium
7/31/2020Wells Fargo & CompanyBoost TargetOverweight$525.00 ➝ $590.00High
7/31/2020CitigroupBoost TargetBuy$525.00 ➝ $625.00High
7/30/2020Wells Fargo & CompanyReiterated RatingBuyHigh
5/21/2020Wells Fargo & CompanyBoost TargetOverweight$495.00 ➝ $525.00Low
5/7/2020CitigroupBoost TargetBuy$480.00 ➝ $525.00Low
4/20/2020CitigroupBoost TargetBuy$425.00 ➝ $480.00Low
3/30/2020Wells Fargo & CompanyLower TargetOverweight$440.00 ➝ $385.00High
3/26/2020BarclaysLower TargetOverweight$435.00 ➝ $430.00Medium
3/20/2020CitigroupLower TargetBuy$450.00 ➝ $425.00High
3/3/2020CitigroupReiterated RatingBuy$450.00N/A
2/14/2020Wells Fargo & CompanyBoost TargetOverweight$430.00 ➝ $440.00High
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$430.00Low
1/6/2020CitigroupInitiated CoverageBuy$450.00High
8/20/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$400.00High
8/2/2019BarclaysBoost TargetOverweight$350.00 ➝ $380.00High
5/9/2019Deutsche Bank AktiengesellschaftBoost TargetBuy$350.00 ➝ $375.00High
5/9/2019BarclaysBoost TargetOverweight$340.00 ➝ $350.00High
3/1/2019Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$330.00 ➝ $350.00Medium
3/1/2019BarclaysBoost TargetOverweight ➝ Overweight$315.00 ➝ $340.00Medium
1/3/2019BarclaysUpgradeEqual Weight ➝ Overweight$315.00Medium
11/2/2018BarclaysLower TargetEqual Weight ➝ Equal Weight$345.00 ➝ $315.00N/A
10/17/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$350.00Low
9/24/2018Jefferies Financial GroupReiterated RatingBuy$420.00High
9/20/2018Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$335.00Low
9/5/2018BarclaysInitiated CoverageEqual Weight$345.00High
8/8/2018Jefferies Financial GroupBoost TargetBuy ➝ Buy$325.00 ➝ $355.00High
3/20/2018Wells Fargo & CompanyBoost TargetOutperform$280.00 ➝ $290.00Low
2/28/2018Wells Fargo & CompanyLower TargetOutperform ➝ Outperform$290.00 ➝ $280.00Medium
2/28/2018Jefferies Financial GroupBoost TargetTop Pick ➝ Buy$325.00High
2/28/2018CitigroupBoost TargetBuy$325.00High
2/16/2018CL KingDowngradeBuy ➝ NeutralMedium
11/29/2017Wells Fargo & CompanyReiterated RatingOutperform$250.00 ➝ $290.00High
(Data available from 11/28/2017 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 2 very positive mentions
  • 22 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/1/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/31/2022
  • 4 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/30/2022
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2022
  • 3 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2022
  • 6 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/28/2022

Current Sentiment

  • 6 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Bio-Rad Laboratories logo
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Read More

Today's Range

Now: $398.41
Low: $396.45
High: $402.77

50 Day Range

MA: $402.34
Low: $351.71
High: $456.01

52 Week Range

Now: $398.41
Low: $344.63
High: $771.69

Volume

202,969 shs

Average Volume

212,565 shs

Market Capitalization

$11.88 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Bio-Rad Laboratories?

The following equities research analysts have issued reports on Bio-Rad Laboratories in the last year: Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., StockNews.com, and TheStreet.
View the latest analyst ratings for BIO.

What is the current price target for Bio-Rad Laboratories?

3 Wall Street analysts have set twelve-month price targets for Bio-Rad Laboratories in the last year. Their average twelve-month price target is $680.00, suggesting a possible upside of 70.7%. Jefferies Financial Group Inc. has the highest price target set, predicting BIO will reach $700.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $640.00 for Bio-Rad Laboratories in the next year.
View the latest price targets for BIO.

What is the current consensus analyst rating for Bio-Rad Laboratories?

Bio-Rad Laboratories currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIO will outperform the market and that investors should add to their positions of Bio-Rad Laboratories.
View the latest ratings for BIO.

What other companies compete with Bio-Rad Laboratories?

How do I contact Bio-Rad Laboratories' investor relations team?

Bio-Rad Laboratories' physical mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company's listed phone number is (510) 724-7000 and its investor relations email address is [email protected] The official website for Bio-Rad Laboratories is www.bio-rad.com. Learn More about contacing Bio-Rad Laboratories investor relations.